18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      PTPσ inhibitors promote hematopoietic stem cell regeneration

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Receptor type protein tyrosine phosphatase-sigma (PTPσ) is primarily expressed by adult neurons and regulates neural regeneration. We recently discovered that PTPσ is also expressed by hematopoietic stem cells (HSCs). Here, we describe small molecule inhibitors of PTPσ that promote HSC regeneration in vivo. Systemic administration of the PTPσ inhibitor, DJ001, or its analog, to irradiated mice promotes HSC regeneration, accelerates hematologic recovery, and improves survival. Similarly, DJ001 administration accelerates hematologic recovery in mice treated with 5-fluorouracil chemotherapy. DJ001 displays high specificity for PTPσ and antagonizes PTPσ via unique non-competitive, allosteric binding. Mechanistically, DJ001 suppresses radiation-induced HSC apoptosis via activation of the RhoGTPase, RAC1, and induction of BCL-X L. Furthermore, treatment of irradiated human HSCs with DJ001 promotes the regeneration of human HSCs capable of multilineage in vivo repopulation. These studies demonstrate the therapeutic potential of selective, small-molecule PTPσ inhibitors for human hematopoietic regeneration.

          Abstract

          Protein tyrosine phosphatase sigma (PTPσ) deficient haematopoietic stem cells (HSCs) demonstrate increased engraftment following transplantation. Here the authors identify a small molecule inhibitor of PTPσ that promotes murine and human haematopoietic stem cell regeneration via induction of the RAC pathway and BCL-X L.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche.

          The quiescent state is thought to be an indispensable property for the maintenance of hematopoietic stem cells (HSCs). Interaction of HSCs with their particular microenvironments, known as the stem cell niches, is critical for adult hematopoiesis in the bone marrow (BM). Here, we demonstrate that HSCs expressing the receptor tyrosine kinase Tie2 are quiescent and antiapoptotic, and comprise a side-population (SP) of HSCs, which adhere to osteoblasts (OBs) in the BM niche. The interaction of Tie2 with its ligand Angiopoietin-1 (Ang-1) induced cobblestone formation of HSCs in vitro and maintained in vivo long-term repopulating activity of HSCs. Furthermore, Ang-1 enhanced the ability of HSCs to become quiescent and induced adhesion to bone, resulting in protection of the HSC compartment from myelosuppressive stress. These data suggest that the Tie2/Ang-1 signaling pathway plays a critical role in the maintenance of HSCs in a quiescent state in the BM niche.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.

            The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase. Activating mutations of SHP2 have been associated with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukaemia, lung and breast cancer and neuroblastoma. SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS–ERK signalling pathway. It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways. Reduction of SHP2 activity suppresses tumour cell growth and is a potential target of cancer therapy. Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-molecule SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation. SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumour xenograft models. Together, these data demonstrate that pharmacological inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration.

              Chondroitin sulfate proteoglycans (CSPGs) present a barrier to axon regeneration. However, no specific receptor for the inhibitory effect of CSPGs has been identified. We showed that a transmembrane protein tyrosine phosphatase, PTPsigma, binds with high affinity to neural CSPGs. Binding involves the chondroitin sulfate chains and a specific site on the first immunoglobulin-like domain of PTPsigma. In culture, PTPsigma(-/-) neurons show reduced inhibition by CSPG. A PTPsigma fusion protein probe can detect cognate ligands that are up-regulated specifically at neural lesion sites. After spinal cord injury, PTPsigma gene disruption enhanced the ability of axons to penetrate regions containing CSPG. These results indicate that PTPsigma can act as a receptor for CSPGs and may provide new therapeutic approaches to neural regeneration.
                Bookmark

                Author and article information

                Contributors
                jchute@mednet.ucla.edu
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                14 August 2019
                14 August 2019
                2019
                : 10
                : 3667
                Affiliations
                [1 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Molecular Biology Institute, , University of California, Los Angeles (UCLA), ; Los Angeles, CA 90095 USA
                [2 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Division of Hematology/Oncology, , Department of Medicine, UCLA, ; Los Angeles, CA 90095 USA
                [3 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, UCLA, ; Los Angeles, CA 90095 USA
                [4 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Jonsson Comprehensive Cancer Center, UCLA, ; Los Angeles, CA 90095 USA
                [5 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Department of Molecular and Medical Pharmacology, , UCLA, ; Los Angeles, CA 90095 USA
                [6 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Department of Chemistry and Biochemistry, , UCLA, ; Los Angeles, CA 90095 USA
                [7 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, California Nanosystems Institute, UCLA, ; Los Angeles, CA 90095 USA
                [8 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Department of Psychiatry and Behavioral Sciences, , UCLA, ; Los Angeles, CA 90095 USA
                [9 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Department of Radiation Oncology, , UCLA, ; Los Angeles, CA 90095 USA
                Author information
                http://orcid.org/0000-0001-6437-1773
                http://orcid.org/0000-0002-1831-1347
                http://orcid.org/0000-0003-2763-7733
                http://orcid.org/0000-0002-8841-0527
                Article
                11490
                10.1038/s41467-019-11490-5
                6694155
                31413255
                1db94cb6-736b-4b5b-ae02-27dc09d47292
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 14 December 2017
                : 18 July 2019
                Funding
                Funded by: FundRef https://doi.org/10.13039/100000060, U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID);
                Award ID: AI067769
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100000050, U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI);
                Award ID: HL086998
                Award ID: U54-HL119893
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100000900, California Institute for Regenerative Medicine (CIRM);
                Award ID: LA1-08014
                Award ID: DISC2-09624
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                cell biology,stem cells,haematopoietic stem cells
                Uncategorized
                cell biology, stem cells, haematopoietic stem cells

                Comments

                Comment on this article